Browse WNT10B

Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Secreted
Domain PF00110 wnt family
Function

Member of the Wnt ligand gene family that encodes for secreted proteins, which activate the Wnt signaling cascade. Specifically activates canonical Wnt/beta-catenin signaling and thus triggers beta-catenin/LEF/TCF-mediated transcriptional programs. Involved in signaling networks controlling stemness, pluripotency and cell fate decisions. Acts in the immune system, mammary gland, adipose tissue, bone and skin.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001942 hair follicle development
GO:0002062 chondrocyte differentiation
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0007050 cell cycle arrest
GO:0007224 smoothened signaling pathway
GO:0007346 regulation of mitotic cell cycle
GO:0007423 sensory organ development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0008544 epidermis development
GO:0009415 response to water
GO:0009894 regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010498 proteasomal protein catabolic process
GO:0010971 positive regulation of G2/M transition of mitotic cell cycle
GO:0014074 response to purine-containing compound
GO:0014706 striated muscle tissue development
GO:0014835 myoblast differentiation involved in skeletal muscle regeneration
GO:0014902 myotube differentiation
GO:0014904 myotube cell development
GO:0016055 Wnt signaling pathway
GO:0016202 regulation of striated muscle tissue development
GO:0021700 developmental maturation
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030278 regulation of ossification
GO:0030282 bone mineralization
GO:0030500 regulation of bone mineralization
GO:0030501 positive regulation of bone mineralization
GO:0030856 regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0031099 regeneration
GO:0031214 biomineral tissue development
GO:0031329 regulation of cellular catabolic process
GO:0031334 positive regulation of protein complex assembly
GO:0031647 regulation of protein stability
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032526 response to retinoic acid
GO:0042176 regulation of protein catabolic process
GO:0042246 tissue regeneration
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0042634 regulation of hair cycle
GO:0042635 positive regulation of hair cycle
GO:0042640 anagen
GO:0042692 muscle cell differentiation
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043254 regulation of protein complex assembly
GO:0043403 skeletal muscle tissue regeneration
GO:0043586 tongue development
GO:0043588 skin development
GO:0044089 positive regulation of cellular component biogenesis
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0044848 biological phase
GO:0044851 hair cycle phase
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0045445 myoblast differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045599 negative regulation of fat cell differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045682 regulation of epidermis development
GO:0045684 positive regulation of epidermis development
GO:0045778 positive regulation of ossification
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045898 regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0045899 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0045931 positive regulation of mitotic cell cycle
GO:0046683 response to organophosphorus
GO:0048634 regulation of muscle organ development
GO:0048641 regulation of skeletal muscle tissue development
GO:0048705 skeletal system morphogenesis
GO:0048741 skeletal muscle fiber development
GO:0048747 muscle fiber development
GO:0048818 positive regulation of hair follicle maturation
GO:0048819 regulation of hair follicle maturation
GO:0048820 hair follicle maturation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050821 protein stabilization
GO:0050909 sensory perception of taste
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0051146 striated muscle cell differentiation
GO:0051216 cartilage development
GO:0051591 response to cAMP
GO:0051599 response to hydrostatic pressure
GO:0051797 regulation of hair follicle development
GO:0051798 positive regulation of hair follicle development
GO:0051884 regulation of anagen
GO:0051885 positive regulation of anagen
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060070 canonical Wnt signaling pathway
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060261 positive regulation of transcription initiation from RNA polymerase II promoter
GO:0060343 trabecula formation
GO:0060346 bone trabecula formation
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061136 regulation of proteasomal protein catabolic process
GO:0061196 fungiform papilla development
GO:0061383 trabecula morphogenesis
GO:0061430 bone trabecula morphogenesis
GO:0061448 connective tissue development
GO:0065004 protein-DNA complex assembly
GO:0070167 regulation of biomineral tissue development
GO:0070169 positive regulation of biomineral tissue development
GO:0070897 DNA-templated transcriptional preinitiation complex assembly
GO:0071107 response to parathyroid hormone
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071320 cellular response to cAMP
GO:0071374 cellular response to parathyroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071425 hematopoietic stem cell proliferation
GO:0071462 cellular response to water stimulus
GO:0071464 cellular response to hydrostatic pressure
GO:0071695 anatomical structure maturation
GO:0071824 protein-DNA complex subunit organization
GO:0072089 stem cell proliferation
GO:0090068 positive regulation of cell cycle process
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0098773 skin epidermis development
GO:0198738 cell-cell signaling by wnt
GO:1901861 regulation of muscle tissue development
GO:1901987 regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902751 positive regulation of cell cycle G2/M phase transition
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005109 frizzled binding
GO:0030545 receptor regulator activity
GO:0030546 receptor activator activity
GO:0048018 receptor agonist activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
hsa04310 Wnt signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04916 Melanogenesis
Reactome R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-1266738: Developmental Biology
R-HSA-500792: GPCR ligand binding
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-195721: Signaling by Wnt
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-3238698: WNT ligand biogenesis and trafficking
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WNT10B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WNT10B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WNT10B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0230.946
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3430.541
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2830.562
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1250.845
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7250.469
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1870.319
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5490.309
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5220.508
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7360.392
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7050.156
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9430.156
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0640.778
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WNT10B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WNT10B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WNT10B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WNT10B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WNT10B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WNT10B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WNT10B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWNT10B
Namewingless-type MMTV integration site family, member 10B
Aliases WNT-12; SHFM6; WNT-10B protein; Protein Wnt-12; Protein Wnt-10b
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WNT10B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.